Companies / Biotechnology
Biohaven licenses IgG degraders to Ono in Asia for $80 million upfront
Ono gains exclusive rights in Japan, South Korea, Taiwan and ASEAN to BHV-1300 and two follow-on degraders, with up to $100 million in near-term payments and roughly 20% royalties. Biohaven keeps US, European and Chinese rights.